Literature DB >> 6693039

Selective and non-selective beta receptor blockade in the reduction of portal pressure in patients with cirrhosis and portal hypertension.

D Westaby, D J Bihari, A E Gimson, I R Crossley, R Williams.   

Abstract

To elucidate the mechanisms by which beta receptor blockade leads to a reduction of portal pressure, 18 patients with cirrhosis and portal hypertension were given comparable doses of propranolol or metoprolol. The fall in portal pressure was more marked with propranolol together with a significant reduction in hepatic blood flow, which was not seen with metoprolol. No correlation between the reduction in cardiac output and the decrease in portal pressure or changes in hepatic blood flow could be elicited in each group, but there was a direct relationship between the decrease in hepatic blood flow and fall in portal pressure in the propranolol treated patients. The difference observed may be related to blockade of beta 2 vasodilator receptors in the splanchnic circulation which will occur only with propranolol and lead to a greater fall in splanchnic blood flow than will be produced by a reduction in cardiac output alone. Metoprolol, by maintaining effective hepatic blood flow, may be preferable to propranolol in patients with severely impaired liver function.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6693039      PMCID: PMC1432254          DOI: 10.1136/gut.25.2.121

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  7 in total

1.  The use of indocyanine green in the measurement of hepatic blood flow and as a test of hepatic function.

Authors:  J CAESAR; S SHALDON; L CHIANDUSSI; L GUEVARA; S SHERLOCK
Journal:  Clin Sci       Date:  1961-08       Impact factor: 6.124

2.  Transection of the oesophagus for bleeding oesophageal varices.

Authors:  R N Pugh; I M Murray-Lyon; J L Dawson; M C Pietroni; R Williams
Journal:  Br J Surg       Date:  1973-08       Impact factor: 6.939

3.  Thermodilution cardiac output determination with a single flow-directed catheter.

Authors:  J S Forrester; W Ganz; G Diamond; T McHugh; D W Chonette; H J Swan
Journal:  Am Heart J       Date:  1972-03       Impact factor: 4.749

4.  Control of the splanchnic circulation in man. Role of beta-adrenergic receptors.

Authors:  H L Price; L H Cooperman; J C Warden
Journal:  Circ Res       Date:  1967-09       Impact factor: 17.367

Review 5.  Liver blood flow. II. Effects of drugs and hormones on liver blood flow.

Authors:  P D Richardson; P G Withrington
Journal:  Gastroenterology       Date:  1981-08       Impact factor: 22.682

6.  Propranolol--a medical treatment for portal hypertension?

Authors:  D Lebrec; O Nouel; M Corbic; J P Benhamou
Journal:  Lancet       Date:  1980-07-26       Impact factor: 79.321

7.  Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a controlled study.

Authors:  D Lebrec; T Poynard; P Hillon; J P Benhamou
Journal:  N Engl J Med       Date:  1981-12-03       Impact factor: 91.245

  7 in total
  15 in total

1.  Evaluation of potential pharmacodynamic and pharmacokinetic interactions between verapamil and propranolol in normal subjects.

Authors:  D L Murdoch; G D Thomson; G G Thompson; G D Murray; M J Brodie; G T McInnes
Journal:  Br J Clin Pharmacol       Date:  1991-03       Impact factor: 4.335

Review 2.  Portal hypertension--25 years of progress.

Authors:  B R MacDougall; D Westaby; L A Blendis
Journal:  Gut       Date:  1991-09       Impact factor: 23.059

Review 3.  Nonselective beta-blockers and development of portal vein thrombosis in liver cirrhosis: a systematic review and meta-analysis.

Authors:  Xiangbo Xu; Xiaozhong Guo; Valerio De Stefano; Gilberto Silva-Junior; Hemant Goyal; Zhaohui Bai; Qingchun Zhao; Xingshun Qi
Journal:  Hepatol Int       Date:  2019-06-07       Impact factor: 6.047

4.  β-Blocker therapy ameliorates hypersplenism due to portal hypertension in children.

Authors:  Ujjal Poddar; Upender Shava; Surender Kumar Yachha; Jaya Agarwal; Sheo Kumar; Sanjay S Baijal; Anshu Srivastava
Journal:  Hepatol Int       Date:  2014-09-23       Impact factor: 6.047

5.  A study of the antiulcer mechanisms of propranolol in rats.

Authors:  S K Kaan; C H Cho
Journal:  Inflamm Res       Date:  1996-08       Impact factor: 4.575

6.  Reductions in portal pressure by selective beta 2-adrenoceptor blockade in patients with cirrhosis and portal hypertension.

Authors:  D Bihari; D Westaby; A Gimson; I Crossley; J Harry; R Williams
Journal:  Br J Clin Pharmacol       Date:  1984-06       Impact factor: 4.335

Review 7.  The medical prevention of variceal bleeding.

Authors:  D Lebrec
Journal:  Intensive Care Med       Date:  1988       Impact factor: 17.440

8.  Controlled trial of propranolol to prevent recurrent variceal bleeding in patients with non-cirrhotic portal fibrosis.

Authors:  C F Kiire
Journal:  BMJ       Date:  1989-05-20

9.  The impairment of lignocaine clearance by propranolol--major contribution from enzyme inhibition.

Authors:  N D Bax; G T Tucker; M S Lennard; H F Woods
Journal:  Br J Clin Pharmacol       Date:  1985-05       Impact factor: 4.335

10.  Effect of nadolol on liver haemodynamics and function in patients with cirrhosis.

Authors:  C Merkel; D Sacerdoti; G F Finucci; R Zuin; G Bazzerla; M Bolognesi; A Gatta
Journal:  Br J Clin Pharmacol       Date:  1986-06       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.